+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biocept Inc (BIOC) - Product Pipeline Analysis, 2019 Update

  • ID: 4612530
  • Company Profile
  • August 2019
  • 40 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Affymax Inc
  • AVIVA Biosciences Corp
  • Celula Inc
  • CoImmune Inc
  • MORE
Summary

Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. Biocept offers related instrumentation, OncoCEE technology, and analytical capabilities for rare event detection and genetic characterization. The company’s OncoCEE platform modifies rare cell capture and analyses methods. It serves cancer diagnostic assays to oncologists and other physicians; hospitals, and cancer centers. Biocept also provides clinical trial and research services to pharmaceutical and biopharmaceutical companies; and clinical research organizations. Biocept is headquartered in San Diego, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Biocept Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Affymax Inc
  • AVIVA Biosciences Corp
  • Celula Inc
  • CoImmune Inc
  • MORE
Biocept Inc Company Overview
  • Biocept Inc Company Snapshot
  • Biocept Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Biocept Inc – Pipeline Analysis Overview
  • Biocept Inc - Key Facts
  • Biocept Inc - Major Products and Services
  • Biocept Inc Pipeline Products by Development Stage
  • Biocept Inc Ongoing Clinical Trials by Trial Status
  • Biocept Inc Pipeline Products Overview
  • Companion Diagnostic Target Selector Test - SCLC
  • Companion Diagnostic Target Selector Test - SCLC Product Overview
  • MicroRNA Test - Lung Cancer
  • MicroRNA Test - Lung Cancer Product Overview
  • OncoCEE - CR (FISH)
  • OncoCEE - CR (FISH) Product Overview
  • preCEED
  • preCEED Product Overview
  • Target Selector CTC Test - ESR1
  • Target Selector CTC Test - ESR1 Product Overview
  • Target Selector CTC Test - ESR1 Clinical Trial
  • Target Selector CTC Test - PTEN Deletion
  • Target Selector CTC Test - PTEN Deletion Product Overview
  • Target Selector ctDNA Test - ALK
  • Target Selector ctDNA Test - ALK Product Overview
  • Target Selector ctDNA Test - ALK Clinical Trial
  • Target Selector ctDNA Test - ESR1
  • Target Selector ctDNA Test - ESR1 Product Overview
  • Biocept Inc - Key Competitors
  • Biocept Inc - Key Employees
  • Biocept Inc - Locations And Subsidiaries
  • Head Office
Recent Developments
  • Biocept Inc, Recent Developments
  • Aug 12, 2019: Biocept reports second quarter 2019 financial results
  • Jun 18, 2019: Biocept announces commercial launch of Target Selector NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel
  • May 28, 2019: Biocept awarded patent in china for its circulating tumor cell platform expanding intellectual property estate to 33 issued patents globally
  • May 20, 2019: Biocept introduces liquid biopsy panel for lung cancer
  • May 08, 2019: Biocept reports first quarter 2019 financial results
  • Mar 28, 2019: Biocept reports 2018 fourth quarter and full year financial results
  • Mar 26, 2019: Biocept broadens commercial focus of its target selector liquid biopsy platform to include urology market segment
  • Mar 18, 2019: Biocept awarded patent in Japan for the capture of rare cells including CTCs from any biological sample of interest with a microchannel device
  • Mar 13, 2019: Biocept expands its pathology partnership offering for liquid biopsy with the addition of several key services
  • Mar 04, 2019: Biocept's liquid biopsy test for ESR1 biomarker detection to be featured in poster presentation at the 2019 AACR Annual Meeting
Appendix
  • Methodology
  • About the Author
  • Contact Us
  • Disclaimer
List of Tables
  • Biocept Inc Pipeline Products and Ongoing Clinical Trials Overview
  • Biocept Inc Pipeline Products by Equipment Type
  • Biocept Inc Pipeline Products by Indication
  • Biocept Inc Ongoing Clinical Trials by Trial Status
  • Biocept Inc, Key Facts
  • Biocept Inc, Major Products and Services
  • Biocept Inc Number of Pipeline Products by Development Stage
  • Biocept Inc Pipeline Products Summary by Development Stage
  • Biocept Inc Ongoing Clinical Trials by Trial Status
  • Biocept Inc Ongoing Clinical Trials Summary
  • Companion Diagnostic Target Selector Test - SCLC - Product Status
  • Companion Diagnostic Target Selector Test - SCLC - Product Description
  • MicroRNA Test - Lung Cancer - Product Status
  • MicroRNA Test - Lung Cancer - Product Description
  • OncoCEE - CR (FISH) - Product Status
  • OncoCEE - CR (FISH) - Product Description
  • preCEED - Product Status
  • preCEED - Product Description
  • Target Selector CTC Test - ESR1 - Product Status
  • Target Selector CTC Test - ESR1 - Product Description
  • Target Selector CTC Test - ESR1 - Biocept's Liquid Biopsy Platform to Evaluate Cerebrospinal Fluid of Breast Cancer Patients for Metastatic Biomarkers
  • Target Selector CTC Test - PTEN Deletion - Product Status
  • Target Selector CTC Test - PTEN Deletion - Product Description
  • Target Selector ctDNA Test - ALK - Product Status
  • Target Selector ctDNA Test - ALK - Product Description
  • Target Selector ctDNA Test - ALK - Evaluation of Liquid Biopsies in Localized and Advanced Lung Cancer Patients
  • Target Selector ctDNA Test - ESR1 - Product Status
  • Target Selector ctDNA Test - ESR1 - Product Description
  • Biocept Inc, Key Employees
  • Glossary
List of Figures
  • Biocept Inc Pipeline Products by Equipment Type
  • Biocept Inc Pipeline Products by Development Stage
  • Biocept Inc Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Affymax Inc
  • CoImmune Inc
  • Celula Inc
  • AVIVA Biosciences Corp
Note: Product cover images may vary from those shown
Adroll
adroll